Mirum Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
July 28 2022 - 9:00AM
Business Wire
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that
it will report second quarter financial results on Thursday, August
4, 2022. That same day, Mirum will host a conference call to
discuss the company’s progress and priorities for 2022.
Conference call details: Thursday, August 4, 2022 4:30 p.m. ET /
1:30 p.m. PT
Dial-in: U.S./Toll-Free: 1 (888) 510-2553 International: 1 (646)
960-0473 Passcode: 9354200
You may also access the call via webcast by visiting the Events
& Presentations section on Mirum’s website. A replay of this
webcast will be available for 30 days.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company
dedicated to transforming the treatment of rare liver diseases.
Mirum’s approved medication is LIVMARLI® (maralixibat) oral
solution which is approved in the U.S. for the treatment of
cholestatic pruritus in patients with Alagille syndrome one year of
age and older. Please view the warnings and precautions available
in the Prescribing information or, for more information, visit
LIVMARLI.com.
Mirum’s late-stage pipeline includes two investigational
treatments for debilitating liver diseases affecting children and
adults. LIVMARLI, an oral ileal bile acid transporter (IBAT)
inhibitor, is currently being evaluated in clinical trials for
pediatric liver diseases and includes the MARCH Phase 3 clinical
trial for progressive familial intrahepatic cholestasis (PFIC) and
the EMBARK Phase 2b clinical trial for patients with biliary
atresia. In addition, Mirum has an expanded access program open
across multiple countries for eligible patients with ALGS and
PFIC.
Mirum has submitted a Marketing Authorization Application to the
European Medicines Agency for LIVMARLI for the treatment of
cholestatic liver disease in patients with Alagille syndrome.
Mirum’s second investigational treatment, volixibat, an oral
IBAT inhibitor, is being evaluated in three potentially
registrational studies including the VISTAS Phase 2b clinical trial
for adults with primary sclerosing cholangitis, the OHANA Phase 2b
clinical trial for pregnant women with intrahepatic cholestasis of
pregnancy, and the VANTAGE Phase 2b clinical trial for adults with
primary biliary cholangitis.
Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220728005326/en/
Media Contact: Erin Murphy media@mirumpharma.com
Investor Contacts: Ian Clements, Ph.D. ir@mirumpharma.com
Sam Martin Argot Partners ir@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Sep 2023 to Sep 2024